Pharmaceutical Executive-02-01-2017

Pharmaceutical Executive

Region in Reform? Access Pains and Gains in Latin America

February 28, 2017

Features

37

2

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Pricing Pressures and Policy Changes

February 06, 2017

Columns

37

2

Congress is poised to tackle exorbitant drug prices through health reform and FDA legislation.

Market Access: Current and Future States

February 01, 2017

Features

37

2

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

Market Access: A UK Perspective

February 01, 2017

Features

37

2

Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.

Country Report: Singapore

February 01, 2017

Special Sponsored Section

37

2

Despite serving as a regional hub for numerous leading global healthcare and life sciences companies-while simultaneously straddling the frontier of biomedical advancement and innovation-Singapore is reinventing itself yet again and spearheading a new model of Asian healthcare.

Pharmaceutical Executive, February 2017 Issue (PDF)

February 01, 2017

Issue PDF

37

2

Click the title above to open the Pharmaceutical Executive February 2017 issue in an interactive PDF format.

Obstacles to Europe's HTA ambitions

January 01, 2017

Columns

37

2

The pursuit of a harmonized European approach to assessing the value of new medicines continues to face roadblocks.